Merck @Merck · 19 Aug 2026
In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely https://t.co/OojdKT5hX1
36 062Views
180Likes
54Reposts
15Replies
29Quotes
17Bookmarks
Is that a lot?
79.4×vs this author's median454 views is typical
91Percentile for this authorof 11 recent posts
5.75×vs 100K–1M median6 271 views is typical
16.59%Reachviews ÷ followers
0.77%Engagement rateof viewers reacted